TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz gGmbH, Mainz, Germany.
Department of Immunology, Leiden University Medical Center, Leiden, Netherlands.
Front Immunol. 2023 Mar 8;14:1102282. doi: 10.3389/fimmu.2023.1102282. eCollection 2023.
The cell line MC38 is a commonly used murine model for colorectal carcinoma. It has a high mutational burden, is sensitive to immune checkpoint immunotherapy and endogenous CD8+ T cell responses against neoantigens have been reported.
Here, we re-sequenced exomes and transcriptomes of MC38 cells from two different sources, namely Kerafast (originating from NCI/NIH, MC38-K) and the Leiden University Medical Center cell line collection (MC38-L), comparing the cell lines on the genomic and transcriptomic level and analyzing their recognition by CD8+ T cells with known neo-epitope specificity.
The data reveals a distinct structural composition of MC38-K and MC38-L cell line genomes and different ploidies. Further, the MC38-L cell line harbored about 1.3-fold more single nucleotide variations and small insertions and deletions than the MC38-K cell line. In addition, the observed mutational signatures differed; only 35.3% of the non-synonymous variants and 5.4% of the fusion gene events were shared. Transcript expression values of both cell lines correlated strongly (p = 0.919), but we found different pathways enriched in the genes that were differentially upregulated in the MC38-L or MC38-K cells, respectively. Our data show that previously described neoantigens in the MC38 model such as Rpl18 and Adpgk were absent in the MC38-K cell line resulting that such neoantigen-specific CD8+ T cells recognizing and killing MC38-L cells did not recognize or kill MC38-K cells.
This strongly indicates that at least two sub-cell lines of MC38 exist in the field and underlines the importance of meticulous tracking of investigated cell lines to obtain reproducible results, and for correct interpretation of the immunological data without artifacts. We present our analyses as a reference for researchers to select the appropriate sub-cell line for their own studies.
MC38 细胞系是一种常用于结直肠癌的鼠模型。它具有较高的突变负担,对免疫检查点免疫疗法敏感,并且已经报道了针对新抗原的内源性 CD8+T 细胞反应。
在这里,我们对来自两个不同来源的 MC38 细胞(即 Kerafast(源自 NCI/NIH,MC38-K)和莱顿大学医学中心细胞系收集(MC38-L))进行了外显子组和转录组重新测序,在基因组和转录组水平上比较了这两种细胞系,并分析了它们与已知新表位特异性的 CD8+T 细胞的识别情况。
数据显示 MC38-K 和 MC38-L 细胞系基因组的结构组成明显不同,并且倍性也不同。此外,MC38-L 细胞系的单核苷酸变异和小插入/缺失数量比 MC38-K 细胞系多约 1.3 倍。此外,观察到的突变特征也不同;非同义变异中只有 35.3%和融合基因事件中只有 5.4%是共享的。两种细胞系的转录表达值相关性很强(p=0.919),但我们发现分别在 MC38-L 或 MC38-K 细胞中上调的基因中富集了不同的途径。我们的数据表明,在 MC38 模型中先前描述的新抗原,如 Rpl18 和 Adpgk,在 MC38-K 细胞系中不存在,因此识别和杀伤 MC38-L 细胞的此类新抗原特异性 CD8+T 细胞不能识别或杀伤 MC38-K 细胞。
这强烈表明至少有两种 MC38 亚系存在于该领域,这强调了仔细跟踪研究细胞系以获得可重复结果的重要性,以及在没有人为干扰的情况下正确解释免疫学数据的重要性。我们将我们的分析结果作为参考,供研究人员为自己的研究选择合适的亚系。